A review of anabolic therapies for osteoporosis

Arthritis Research and Therapy

Volumn 5, Issue 5, 2003, Pages 214-222

  Lane, Nancy E ^a   Kelman, Ariella ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anabolic; Bone morphogenic protein 2 (BMP 2); Bone morphogenic protein 7; Parathyroid hormone hPTH (1 84); Parathyroid hormone rhPTH (1 34)

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CERIVASTATIN; ESTROGEN; ETIDRONIC ACID; FIBROBLAST GROWTH FACTOR; FLUORIDE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MEVINOLIN; NITRIC OXIDE SYNTHASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PITAVASTATIN; PLACEBO; RALOXIFENE; RECOMBINANT GROWTH HORMONE; RECOMBINANT PROTEIN; SIMVASTATIN; SOMATOMEDIN C; STRONTIUM; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

BONE INJURY; BONE MASS; BONE STRENGTH; BONE STRUCTURE; BREAST CANCER; CELL ACTIVITY; CELL COUNT; CELL STIMULATION; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FRACTURE HEALING; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; LIFESPAN; METABOLIC DISORDER; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW;

ANABOLIC AGENTS; ANIMALS; GROWTH SUBSTANCES; HUMANS; OSTEOCLASTS; OSTEOPOROSIS; PEPTIDE HORMONES;

EID: 0141857862     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Lee CA, Einhorn TA: Introduction to normal bone physiology and pathophysiology. In Osteoporosis. 2nd edition. Edited by Marcus R, Feldman D, Kelsey J. San Francisco, CA: Academic Press; 2001:3-19.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
3. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures. Am J Med 2000, 109:267-276.
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637-645.
5. Rubin MR, Bilizekin JP: New anabolic therapies for osteoporosis. Curr Opin Rheumatol 2002, 14:433-440.
6. Crandall C: Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002, 162:2297-2309.
7. Albright F, Aub JC, Bauer W: Hyperparathyroidism: a common and polymorphic condition illustrated by seventeen proven cases from one clinic. JAMA 1934, 102:1276-1287.
8. Albright F, Reifenstein EC: The Parathyroid Glands and Metabolic Bone Disease. Baltimore: Williams & Wilkins; 1948.
9. Hock JM, Gera I, Fonseca J, Raisz LG: Human parathyroid hormone (1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988, 122:2899-2904.
10. Lane NE, Thompson JM, Strewler G, Kinney JH: Intermittent treatment with human parathyroid hormone (hPTH 1-34) increased trabecular bone mass but not connectivity in osteopenic rats. J Bone Miner Res 1996, 10:1470-1477.
11. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
12. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezilkian J, Lindsay R: Effects of daily treatment with, parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
13. Whitfield JF: How to grow bone to treat osteoporosis and mend fractures. Curr Rheumatol Rep 2003, 5:45-56.
14. Lane NE, Yao W, Kinney JH, Modin G, Baloosh M, Wronski TJ: Both hPTH (1-34) increase trabecular bone mass in osteopenic rats however they have different effects on trabecular bone structure. J Bone Min Res 2003, in press.
15. Lane N, Yao W, Arnaud C: Association of serum RANKL and OPG levels with other biochemical markers of bone turnover in glucocorticoid-induced osteoporosis patients treated with hPTH (1-34) [abstract]. J Bone Miner Res 2002, Suppl 1:F366.
16. Lane NE, Yao W, Arnaud CD: Changes in serum RANKL, OPG and IL-6 during hPTH (1-34) administration in patients with glucocorticoid induced osteoporosis. J Bone Miner Res 2003, Suppl 1: in press.
17. Mitnick MA, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz MC, Insogna K:Parathyroid hormone induces hepatic production of bioactive IL-6 and its soluble receptor. Am J Physiol Endocrinol Metab 2001, 280:E405-E412.
18. Greenfield EM, Horowitz Lavish SA: Stimulation of parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J Biol Chem 1996, 271:10984-10989.
19. Fu Q, Jilka RL, Manolagas SC, O'Brien CA: Parathyroid hormone stimulates receptor activator of NFkB ligand and inhibits osteoprotegrin expression via protein kinase A activation of cAMP-response element binding protein. J Biol Chem 2002, 277:48868-48875.
20. Lee S-K, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegrin messenger ribonucleic acid expression with osteoclast-like cell formation. Endocrinology 1999, 140:3552-3561.
21. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157-165.
22. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezilkian JP: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076.
23. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
24. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F: Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
25. Roe E, Sanchez S, del puerto G, et al. Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increase in postmenopausal osteoporosis-results from a placebo-controlled randomized trial [abstract]. J Bone Miner Res, 1999, Suppl 1:S137.
26. Cann C, Roe EB, Sanchez SD, et al.: PTH effect in the femur: envelope-specific responses by 3DQCT in postmenopausal women [abstract]. J Bone Miner Res 1999, Suppl 1:S137.
27. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
28. Black DM, Rosen C, Greenspan S, Ensrud K, Bilezikian J, McGowan J: PTH and bisphosphonates in the treatment of osteoporosis: design of the PTH and alendronate (PATH) trial [abstract]. In ASBMR 23rd annual meeting, 2001:5287.
29. Finkelstein JS, Hayes A, Rao A, Neer RM: Effects of parathyroid hormone, alendronate or both on bone mineral density in osteoporotic men [abstract]. J Bone Miner Res 2002, Suppl 1:1007.
30. Neer R, Hayes A, Rao A, Finkelstein J: Effects of parathyroid hormone, alendronate, or both on bone density in osteoporotic postmenopausal women [abstract]. J Bone Miner Res 2002, Suppl 1:1039.
31. Ettinger B, San Martin JA, Crans G, Pavo I: Early response of bone turnover markers and bone mineral density to teriparatide (rhPTH 1-34) in postmenopausal women previously treated with an anti-resorptive agent [abstract]. J Bone Miner Res 2002, Suppl 1:1136.
32. Horwitz M, Stewart A, Greenspan SL: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab, 2003, 88:569-575.
33. Wuster C, Rosen C: Growth hormone, insulin-like growth factors. Potential applications and limitations in the management of osteoporosis. In Osteoporosis. 2nd edition. Edited by Marcus R, Feldman D, Kelsey J. San Francisco, CA: Academic Press; 2001: 747-767.
34. Rosen, T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtson B-A: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997, 137:240-245.
35. Wuster C, Abs R, Bengtsson B-A, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monsom JP, Westberg B, Wilton, P: The incidence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001, 16:398-405.
36. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenkler RA, Cohn L, Rudman IW, Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 1990, 323:1-6.
37. Yakar S, Rosen CJ: From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Proc Soc Exp Biol Med 2003, 228:245-252.
38. Hankinson SE, Willet WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
39. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999, 91:620-625.
40. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998, 279:563-566.
41. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson, B: Growth hormone increases bone mineral content in post-menopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res 2003, 18:393-405.
42. Reginster JY: Strontium ranelate in osteoporosis. Curr Pharm Des 2002, 8:1907-1916.
43. Marie PJ, Hott M, Modrowski D, De Pollack C, Guillemain J, Deloffre P, Tsouderos Y: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993, 8:607-615.
44. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C: Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002, 13:925-931.
45. Reginster JY, Hoszowski K, Roces Varela A, Balogh A, Clements M, Fiore C, Cormier C, Schmidt WE, Jensen JB, Prince R, Raeman F, Rizzoli R, Meunier PJ: Strontium ranelate: a new effective antiosteoporotic treatment reducing the incidence of vertebral and non vertebral fractures in postmenopausal women with osteoporosis. In International Osteoporosis Society meeting. June 2003; Osaka, Japan, in press.
46. Meunier PJ, Reginster JY: Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003, Suppl 3:66-76.
47. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1546-1549.
48. Garrett IR, Gutierrez G, Chen D, et al.: Statins stimulate bone formation by enhancing eNOS expression [abstract]. J Bone Miner Res 2001, 16:S141.
49. van't Hof RJ, Ralston SH: Nitric oxide and bone. Immunology 2001, 103:113-118.
50. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R: Pitavastatin-enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001, 287:337-342
51. Wang GJ, Chung KC, Shen WJ: Lipid-clearing agents in steroid-induced osteoporosis. J Formos Med Assoc 1995, 94:589-592.
52. Cosman F, Nieves J, Zion M, et al.: Effects of short-term cerivastatin on bone turnover [abstract]. J Bone Miner Res 2001, 16:S29.
53. Bauer: Arch Int Med, in press.
54. Bauer DC: HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003, 4:273-282
55. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N: Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001, 357:509-512.
56. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley G, Passaro MD, Jackson RD: Statin use, clincal fracture, and bone mineral density in post-menopausal women: Results from the women's health initiative observational study. Annal Int Med 2003, 139:97-104
57. Locklin RM, Oreffo ROC, Triffit JT: Effects of TGFB and bFGF on the differentiation of human bone marrow stromal fibroblasts. Cell Biol Int 1999, 23:185-194.
58. Saadeh PB, Mehrara BJ, Steinbrech IDS, Dudziak ME, Greenwald JA, Luchs JS, Spector JA, Ueno H, Gittes GK, Longaker MT: Transforming growth factor-B1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol 1999, 277:C628-C637.
59. Nagai H, Tsukuda R, Mayahara H: Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 1995, 16:367-373.
60. Pun S, Florio CL, Wronski TJ: Anabolic effects of basic fibroblast growth factor in the tibial diaphysis of ovariectomized rats. Bone 2000, 27:197-202.
61. Wronski TJ, Ratkus AM, Thomsen JS, Vulcan O, Mosekilde L: Sequential treatment with basic fibroblast growth factor and parathyroid hormone restores lost cancellous bone mass and strength in the proximal tibia of aged ovariectomized rats. J Bone Miner Res 2001 16:1399-1407.
62. Lane NE, Kumer J, Yao W, Breunig T, Wronski T, Modin G, Kinney JH: Basic fibroblast growth factor forms new trabeculae that physically connect with pre-existing trabeculae, and this new bone is maintained with an anti-resorptive agent and enhanced with an anabolic agent in an osteopenic rat model. Osteoporos Int 2003, 14:374-352.
63. Street J, Bao, M, deGuzman L, Bunting S, Peale Jr. FV, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RAD, Filvaroff EH: Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 2002 99: 9656-9661.
64. Wang EA, Israel DI, Kelly S, Luxenberg DP: Bone morphogenetic protein-2 causes commitment and differentiation in C3h10T1/2 and 3T3 cells. Growth Factors 1993 9:57-71.
65. Ahrens M, Ankenbauer T, Schroder D, Hollnagel A, Mayer H, Gross G: Expression of human bone morphogenetic proteins -2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. DNA Cell Biol 1993 12:871-880.
66. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimuzu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S., Kishimoto T: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
67. Onishi T, Ishidou Y, Nagamine T, Yone K, Imamura T, Kato M, Sampath TK, ten Dijke P, Sakou T: Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats. Bone 1998, 22:605-612.
68. Welch RD, Jones AI, Bucholz RW, Reinert CM, Tjia JS, Pierce WA, Wozney JM, Li XJ: Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998, 13:1483-1490.
69. Bouxsein ML Turek TJ, Blake CA, D'Augusta D, Li X, Stevens M, Seeherman HJ, Wozney JM: Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg 2001, 83-A:1219-1230.
70. Govender S, Csimma C, Genant HK, Valentin-Opran A: Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures. J Bone Joint Surg 2002, 84-A:2123-2134.
71. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderstom RA: Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002, 27:2396-2408.
72. BMP 2-Genetics Institute/ Medtronic-Sofamor Danek/Integra. Bone morphogenetic protein 2-Genetics Institute/ Medtronic-Sofamor Danek/Integra, INFUSE Bone Graft, recombinant human bone morphogenetic protein 2-Genetics Institute/Mectronic-Sofamor Danek/Integra, RhBMP 2-Genetics Institute/Medtronic-Sofamor Danek/Integra. BioDrugs 2002, 16:376-377.
73. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA: Growth factor regulation of fracture repair. J Bone Miner Res 1999, 14: 1805-1815.
74. Reddi AH: Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am 2001, Suppl 1 (Pt 1):S1-6.
75. Geesink RG, Hoefnagels NH, Bulstra SK: Osteogenic activity of OP-1 bone morphogenic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 1999 81:710-718.
76. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S: Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001, Suppl 1 (Pt 2):S151-S158.
77. Cook SD, Dalton JE, Tan EH, Whitecloud TS 3rd, Rueger DC; In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine 1994, 19:1655-1663.
78. Margolin MD, Cogan AG, Taylor M, Buck D, McAllister TN, Toth C, McAllister BS: Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral. J Periodontol 1998, 69:911-919.
79. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ 3rd: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990 322:802-809.
80. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, Parfitt AM:A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991, 1:155-161.
81. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR:Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1999, 123:401-408.
82. Ringe JD, Rovati LC: Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 2001, 69:252-255.